FINANCING
Who is raising money: selling new shares, filing room to sell more later, or borrowing. New shares give every holder a smaller slice.
14 filings from 12 companies in the last 7 days, 85 in 30. $17.9B of room filed to sell more. The biggest this week: CLPT, $100M of at-the-market programme.
Biggest this week
Large against the company
No share sale with a size and a market value on file in this window.
Filing again and again
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Key
Shares soldSold over timeRoom to sell laterBorrowingReverse splitThe stock since the filing
Newest first. A company with several filings is one row; open it for each.
- MDAISpectral AI, Inc.Equity line$15.0M45% of value−20.6%8-K ↗
- HSCSHeartSciences Inc.At-the-market programme, with Maxim Group$50.0M4.9x value−13.8%424B5 ↗
- CLPTClearPoint Neuro, Inc.At-the-market programme, with Stifel, Nicolaus$50.0M23% of value−10.4%8-K ↗
- CLPTClearPoint Neuro, Inc.At-the-market programme, with Stifel, Nicolaus$100.0M45% of value−10.4%S-3 ↗
- PZGParamount Gold Nevada Corp.At-the-market programme, with Cantor Fitzgerald$20.0M26% of value−10.0%424B5 ↗
- MEDSDataMEDS AI, Inc.At-the-market programme, with Dawson James Securities$7.0M92% of value+109.3%424B5 ↗
- MEDSDataMEDS AI, Inc.At-the-market programme, with Dawson James Securities$10.0M1.3x value+80.1%424B5 ↗
- NNVCNanoViricides, Inc.At-the-market programme$8.4M29% of value−1.7%424B5 ↗
- XGNExagen Inc.At-the-market programme, with TD Securities (USA)$50.0M54% of value−4.0%424B5 ↗
- XGNExagen Inc.At-the-market programme, with TD Securities (USA)$50.0M54% of value−49.2%S-3 ↗
- AZRAzora Therapeutics, Inc.At-the-market programme, with Jefferies$20.0M36% of valueS-3 ↗
- TTRXTurn Therapeutics Inc.At-the-market programme, with TD Securities (USA)$50.0M20% of value−5.3%424B5 ↗
- TTRXTurn Therapeutics Inc.At-the-market programme, with TD Securities (USA)$50.0M20% of value−14.6%S-3 ↗
- MPLTMapLight Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M30% of value−18.1%S-3 ↗
- TET1 Energy Inc.At-the-market programme, with Roth Capital Partners$100.0M29% of value−42.4%424B5 ↗
- OPTXSyntec Optics Holdings, Inc.At-the-market programme, with H.C. Wainwright$50.0M20% of value−11.2%S-3 ↗
- NAKANakamoto Inc.At-the-market programme, with TD Securities (USA)$4.99B−31.2%424B5 ↗
- CINGCingulate Inc.At-the-market programme, with A.G.P./Alliance Global Partners$100.0M1.5x value+4.9%8-K ↗
- CINGCingulate Inc.At-the-market programme$100.0M1.5x value+4.9%424B3 ↗
- VATEINNOVATE Corp.At-the-market programme$50.0M1.0x value−22.3%424B5 ↗
- CENNCenntro Inc.At-the-market programme, with Pacific Century Securities$100.0M−13.7%424B5 ↗
- CTGOContango Silver & Gold Inc.At-the-market programme, with Cantor Fitzgerald$75.0M24% of value−20.3%424B5 ↗
- INBXInhibrx Biosciences, Inc.At-the-market programme, with Stifel, Nicolaus$150.0M15% of value−17.2%S-3ASR ↗
- LINKInterlink Electronics, Inc.At-the-market programme$7.2M22% of value−26.0%8-K ↗
- LINKInterlink Electronics, Inc.At-the-market programme, with A.G.P./Alliance Global Partners$7.2M22% of value−26.0%424B5 ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−31.4%424B5 ↗
- FATEFate Therapeutics, Inc.At-the-market programme, with Leerink Partners$100.0M89% of value−50.3%S-3 ↗
- AIROAIRO Group Holdings, Inc.At-the-market programme, with Cantor Fitzgerald$50.0M44% of value−36.0%S-3 ↗
- SPCEVirgin Galactic Holdings, Inc.At-the-market programme, with Jefferies$250.0M1.6x value−61.0%424B5 ↗
- CADLCandel Therapeutics, Inc.At-the-market programme, with Jefferies$50.0M13% of value−39.9%424B5 ↗
- MGTXMeiraGTx Holdings plcAt-the-market programme, with BofA Securities$100.0M13% of value−17.6%S-3ASR ↗
- PROKProKidney Corp.At-the-market programme, with Jefferies$200.0M48% of value−8.0%424B5 ↗
- NHPNational Healthcare Properties, Inc.At-the-market programme$300.0M20% of value−5.9%8-K ↗
- NHPNational Healthcare Properties, Inc.At-the-market programme$300.0M20% of value−5.9%424B5 ↗
- KURAKura Oncology, Inc.At-the-market programme, with Leerink Partners$150.0M24% of value−8.7%S-3ASR ↗
- FWDIForward Industries, Inc.At-the-market programme, with Cantor Fitzgerald$4.00B−37.4%8-K ↗
- FWDIForward Industries, Inc.At-the-market programme$4.00B−42.5%424B5 ↗
- ATRAAtara Biotherapeutics, Inc.At-the-market programme, with TD Cowen$23.0M36% of value−21.9%S-3 ↗
- PACBPacific Biosciences of California, Inc.At-the-market programme, with Allen$100.0M20% of value−27.2%8-K ↗
- PACBPacific Biosciences of California, Inc.At-the-market programme, with Allen$100.0M20% of value−27.2%424B5 ↗
- OVIDOvid Therapeutics Inc.At-the-market programme, with Cantor Fitzgerald$75.0M18% of value−22.8%S-3 ↗
- TSLXSixth Street Specialty Lending, Inc.At-the-market programme$100.0M6.2% of value−5.4%8-K ↗
- HYPRHyperfine, Inc.At-the-market programme, with B. Riley Securities$50.0M86% of value−22.7%S-3 ↗
- CAPSCapstone Holding Corp.Equity line with Tumim Stone Capital$20.0M−24.2%8-K ↗
- USGOU.S. GoldMining Inc.At-the-market programme$3.2M6.0% of value−30.2%424B5 ↗
- GNLGlobal Net Lease, Inc.At-the-market programme, with BofA Securities$300.0M22% of value−12.4%424B5 ↗
- ZBIOZenas BioPharma, Inc.At-the-market programme, with Jefferies$200.0M12% of value−15.6%424B5 ↗
- ATYRaTyr Pharma, Inc.At-the-market programme, with Jefferies$80.0M−39.8%424B5 ↗
- FDUSFidus Investment CorporationAt-the-market programme, with Raymond James & Associates$400.0M55% of value−6.6%424B3 ↗
- VSTMVerastem, Inc.At-the-market programme, with Cantor Fitzgerald$100.0M13% of value−32.5%S-3ASR ↗